Chowdhury, Namara MariamKhandaker, Meharin2026-08-242026-08-2420262026-06ID 21146034https://hdl.handle.net/10361/29490This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2026.Cataloged from PDF version of thesisIncludes bibliographical references (pages 26-29).Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. PD-1 and PD-L1 inhibitors have recently shown promise when combined with chemotherapy to treat TNBC. This thesis aimed to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in TNBC through a meta-analysis of randomized controlled trials. Nine randomized controlled trials were included. This study covers both early-stage and advanced or metastatic TNBC. The main efficacy outcomes were pathological complete response (pCR) in early-stage TNBC and objective response rate (ORR) in advanced or metastatic TNBC. Safety was assessed using Grade ≥3 adverse events. The pooled analysis showed that PD-1/PD-L1 inhibitor plus chemotherapy significantly improved pCR in early-stage TNBC (OR = 1.82, 95% CI: 1.43-2.31; p < 0.00001) and ORR in advanced or metastatic TNBC (OR = 1.28, 95% CI: 1.09-1.51; p = 0.003). Safety analysis showed no statistically significant increase in Grade ≥3 adverse events with immunotherapy-based treatment compared with control therapy (RR = 1.04, 95% CI: 0.99-1.11; p = 0.14). Overall, the findings suggest that PD-1/PD-L1 inhibitors combined with chemotherapy provide meaningful clinical benefit in TNBC.41 pagesen-USAttribution-NonCommercial-NoDerivatives 4.0 InternationalBRAC University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.http://creativecommons.org/licenses/by-nc-nd/4.0/Breast cancerTriple-negative breast cancerTNBCImmunotherapyPathological complete responsePCRObjective response rateORRPD-L1 inhibitorsPD-1 inhibitorsClinical trials--Statistical methods.Breast--Cancer--Treatment.Cancer--Immunotherapy.Thesis